Oncolytics Biotech (ONCY) Equity Income (2014 - 2016)

Oncolytics Biotech (ONCY) has 3 years of Equity Income data on file, last reported at $141295.0 in Q1 2016.

• On a quarterly basis, Equity Income rose 146.3% year-over-year to $141295.0 in Q1 2016; TTM through Mar 2016 was -$444947.0, a N/A change from a year earlier, with the FY2025 full-year figure at -$388000.0, changed N/A from the prior year.
• Equity Income for Q1 2016 stood at $141295.0, up from -$305156.0 in the prior quarter.
• Over the last five years, Equity Income for ONCY reached as high as $141295.0 in Q1 2016 and fell as low as -$305156.0 in Q1 2015.
• Historically, Equity Income has averaged -$84175.4 across 3 years, with a median of $24070.0 in 2014.
• Across the five-year window, Equity Income sank 1367.79% in 2015 and soared 146.3% in 2016, its largest moves.
• Year by year, Equity Income stood at $24070.0 in 2014, then sank by 1367.79% to -$305156.0 in 2015, then surged by 146.3% to $141295.0 in 2016.
• Per Business Quant data, the three most recent Equity Income figures were $141295.0 in Q1 2016, -$305156.0 in Q4 2015, and -$305156.0 in Q1 2015.